International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 4.28.2022
father and son on computer
pfw 2022 new frontier banner
IMF Patient and Family Webinar: New Frontiers in Myeloma Care
The IMF Patient and Family Webinar, on Saturday, May 14 at 10 a.m. PST / 11 a.m. MST /12 p.m. CT/ 1 p.m. ET, will focus on “New Frontiers in Myeloma Care.” IMF Chairman Dr. Brian G.M. Durie will moderate presentations with the following myeloma experts: Yi Lin, MD, PhD (Mayo Clinic — Rochester, MN), IMF Nurse Leadership Board Member Ann McNeill RN, MSN, APN (John Theurer Cancer Center, Hackensack University Medical Center — Hackensack, NJ), and Nikhil Munshi, MD (Dana-Farber Cancer Institute — Boston, MA). The webinar will conclude with a summary panel discussion, a webinar survey, and closing remarks. You won’t want to miss this lively webinar. At the end of the presentations, participants will have time to ask questions.
register button
u darzalex and u darzalex faspro promo
Download Understanding DARZALEX and DARZALEX FASPRO — 2022 edition
Darzalex® (daratumumab) is the first monoclonal antibody approved by the FDA that targets the CD38 protein on the surface of myeloma cells, causing myeloma cell death. Darzalex Faspro® (daratumumab + hyaluronidase-fihj) is a newer formulation of this targeted therapy. There are numerous FDA-approved regimens with Darzalex or Darzalex Faspro that are used throughout the myeloma disease course — from frontline therapy to the relapsed and refractory setting — and many ongoing myeloma clinical trials are investigating additional indications. Get your FREE copy of the IMF’s Understanding DARZALEX® (daratumumab) intravenous infusion and DARZALEX FASPRO® (daratumumab + hyaluronidase-fihj) subcutaneous injection in printed form or as a downloadable PDF with hyperlinks to informative resources.
download button
doctor mikhael facebook replay video
Watch the Replay: IMF Chief Medical Officer Dr. Joseph Mikhael on Facebook Live
On April 19, Tuesday, Dr. Mikhael went LIVE on Facebook to address disparities in multiple myeloma and the path to health equity. In case you missed it, you can watch the replay on YouTube. Dr. Mikhael discusses disparities in myeloma treatment and diagnosis, representation in clinical trials, the importance of achieving health equity, and what actions are being taken to do so, in this insightful 30-minute video. Never miss another IMF Facebook Live event — join our online community by liking the IMF's Facebook page!
ons banner 2022 with speakers in image
Congratulations to the NLB Featured Speakers of the IMF 1.5 CNE Symposium at ONS 2022!
The IMF 1.5 CNE Symposium, “New Drugs, Regimens, and Strategies for Multiple Myeloma: Case Studies for Nurses” at ONS 2022 was successfully held on Thursday, April 28, in Anaheim, CA. Three highly experienced nurses shared their expertise using real-life patient case scenarios with a focus on clinical pearls and practical solutions during the symposium. The IMF congratulates featured speakers: Beth Faiman, Donna D. Catamero, and Kim Noonan for providing helpful nursing insights and take-home tools for both experienced and new oncology nurses to implement and share with patients and colleagues.
group of runners in a race
This Week: The 14th Annual Miles for Myeloma 5K Run/Walk Hybrid Race
The 14th Annual Miles for Myeloma 5K Run/Walk is officially a hybrid race and will be held this Saturday, April 30, 8:00 a.m. ET at FDR Park in Philadelphia, PA. For those who are unable to attend in person but would still want to be a part of this exciting event, we will continue with our Virtual Race. Participants who wish to attend in person may join us at FDR Park. For more information or to register for this event, please visit the IMF website or email Ilana Kenville, IMF Race Producer at
join now button
ask dr durie video about immune therapies
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
What should myeloma patients know about the new immune therapies?
Watch Now
Online Patient Forum

Smart Patients: Join the Conversation
Clinical Trial Fact Sheets

CANOVA Trial (Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Upcoming Events

Donate Now
RIMMSG Comedy Fundraiser

Register Now
14th Annual Czerkies Memorial Golf Outing

Learn More
Grand Tour of Scotland Whisky Tasting
Webinar Replays
Watch the Replay
Regional Community Workshop — West South Central

Watch the Replay
Regional Community Workshop — Tri-State

Watch the Replay
Are Side Effects Impacting Your Quality of Life?

See also, all of our events.

We Thank Our Sponsors:

Amgen, Bristol Myers Squibb, GSK, Janssen Oncology, and Karyopharm Therapeutics
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page